

Reporting Summary

Nature Portfolio wishes to improve the reproducibility of the work that we publish. This form provides structure for consistency and transparency in reporting. For further information on Nature Portfolio policies, see our [Editorial Policies](#) and the [Editorial Policy Checklist](#).

Statistics

For all statistical analyses, confirm that the following items are present in the figure legend, table legend, main text, or Methods section.

n/a Confirmed

- | | | |
|-------------------------------------|-------------------------------------|--|
| <input type="checkbox"/> | <input checked="" type="checkbox"/> | The exact sample size (n) for each experimental group/condition, given as a discrete number and unit of measurement |
| <input type="checkbox"/> | <input checked="" type="checkbox"/> | A statement on whether measurements were taken from distinct samples or whether the same sample was measured repeatedly |
| <input type="checkbox"/> | <input checked="" type="checkbox"/> | The statistical test(s) used AND whether they are one- or two-sided
<i>Only common tests should be described solely by name; describe more complex techniques in the Methods section.</i> |
| <input checked="" type="checkbox"/> | <input type="checkbox"/> | A description of all covariates tested |
| <input checked="" type="checkbox"/> | <input type="checkbox"/> | A description of any assumptions or corrections, such as tests of normality and adjustment for multiple comparisons |
| <input type="checkbox"/> | <input checked="" type="checkbox"/> | A full description of the statistical parameters including central tendency (e.g. means) or other basic estimates (e.g. regression coefficient) AND variation (e.g. standard deviation) or associated estimates of uncertainty (e.g. confidence intervals) |
| <input type="checkbox"/> | <input checked="" type="checkbox"/> | For null hypothesis testing, the test statistic (e.g. F , t , r) with confidence intervals, effect sizes, degrees of freedom and P value noted
<i>Give P values as exact values whenever suitable.</i> |
| <input checked="" type="checkbox"/> | <input type="checkbox"/> | For Bayesian analysis, information on the choice of priors and Markov chain Monte Carlo settings |
| <input checked="" type="checkbox"/> | <input type="checkbox"/> | For hierarchical and complex designs, identification of the appropriate level for tests and full reporting of outcomes |
| <input checked="" type="checkbox"/> | <input type="checkbox"/> | Estimates of effect sizes (e.g. Cohen's d , Pearson's r), indicating how they were calculated |

Our web collection on [statistics for biologists](#) contains articles on many of the points above.

Software and code

Policy information about [availability of computer code](#)

Data collection Data were collected in Microsoft Excel version 16.77. Quantification data were collected via Bio-1D version 11.0 or Fiji (ImageJ version 1.54p).

Data analysis Statistical analyses were performed in Microsoft Excel version 16.77 or Prism version 9.0.2.

For manuscripts utilizing custom algorithms or software that are central to the research but not yet described in published literature, software must be made available to editors and reviewers. We strongly encourage code deposition in a community repository (e.g. GitHub). See the Nature Portfolio [guidelines for submitting code & software](#) for further information.

Data

Policy information about [availability of data](#)

All manuscripts must include a [data availability statement](#). This statement should provide the following information, where applicable:

- Accession codes, unique identifiers, or web links for publicly available datasets
- A description of any restrictions on data availability
- For clinical datasets or third party data, please ensure that the statement adheres to our [policy](#)

Source data are provided with this paper.

Research involving human participants, their data, or biological material

Policy information about studies with [human participants or human data](#). See also policy information about [sex, gender \(identity/presentation\), and sexual orientation](#) and [race, ethnicity and racism](#).

Reporting on sex and gender n/a

Reporting on race, ethnicity, or other socially relevant groupings n/a

Population characteristics n/a

Recruitment n/a

Ethics oversight n/a

Note that full information on the approval of the study protocol must also be provided in the manuscript.

Field-specific reporting

Please select the one below that is the best fit for your research. If you are not sure, read the appropriate sections before making your selection.

☒ Life sciences ☐ Behavioural & social sciences ☐ Ecological, evolutionary & environmental sciences

For a reference copy of the document with all sections, see nature.com/documents/nr-reporting-summary-flat.pdf

Life sciences study design

All studies must disclose on these points even when the disclosure is negative.

Sample size No specific sample size calculation was performed.

Data exclusions No data were excluded.

Replication All attempts at replication were successful.

Randomization Samples in this studies were allocated randomly.

Blinding n/a

Reporting for specific materials, systems and methods

We require information from authors about some types of materials, experimental systems and methods used in many studies. Here, indicate whether each material, system or method listed is relevant to your study. If you are not sure if a list item applies to your research, read the appropriate section before selecting a response.

Materials & experimental systems

n/a Involved in the study

☐ ☒ Antibodies

☐ ☒ Eukaryotic cell lines

☒ ☐ Palaeontology and archaeology

☒ ☐ Animals and other organisms

☒ ☐ Clinical data

☒ ☐ Dual use research of concern

☒ ☐ Plants

Methods

n/a Involved in the study

☒ ☐ ChIP-seq

☒ ☐ Flow cytometry

☒ ☐ MRI-based neuroimaging

Antibodies

Antibodies used

Goat polyclonal Anti-mouse IgG-HRP, 1:10000, Dianova 115-035-146

Goat polyclonal Anti-rabbit IgG-HRP, 1:10000, Dianova 111-035-144

Goat polyclonal Anti-Yra1, 1:2000, Santa Cruz sc-13930

Mouse monoclonal Anti-GFP, 1:5000, Thermo Fisher MA5-15256

Mouse monoclonal Anti-Nop1, 1:4000, Santa Cruz
 Rabbit polyclonal Anti-GFP, 1:4000, ChromoTek PABG1
 Rabbit polyclonal Anti-Mex67, 1:10000, Davids Biotechnology
 Rabbit polyclonal Anti-Aco1, 1:4000, from Uli Mühlenhoff, Marburg (Germany)
 Rabbit polyclonal Anti-Hem15, 1:5000, from Uli Mühlenhoff, Marburg (Germany)
 Rabbit polyclonal Anti-Zwf1, 1:4000, from Uli Mühlenhoff, Marburg (Germany)
 Sheep Anti-Digoxigenin-Fluorescein (FITC), 1:200, Roche 11207741910

Validation

Most antibodies are commercially available and validated. Antibodies derived from Uli Mühlenhoff were used by several published studies (e.g., PMID: 41505105, 37351636, 36305816) and therefore also validated.

Eukaryotic cell lines

Policy information about [cell lines and Sex and Gender in Research](#)

Cell line source(s)

HCT116 (RRID:CVCL_0291; ATCC) human colorectal carcinoma cells (male origin)

Authentication

Authentication was confirmed by the supplier (ATCC)

Mycoplasma contamination

Cells were not tested for mycoplasma contamination

Commonly misidentified lines
(See [ICLAC](#) register)

HCT116 is not listed in the ICLAC register of commonly misidentified cell lines

Plants

Seed stocks

n/a

Novel plant genotypes

n/a

Authentication

n/a